West Announces Third-Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
West Pharma (WST) Tops Q3 EPS by 16c, Revenues Beat; Raises FY20 EPS/Revenue Guidance Above Consensus
October 22, 2020 6:11 AM EDTWest Pharma (NYSE: WST) reported Q3 EPS of $1.15, $0.16 better than the analyst estimate of $0.99. Revenue for the quarter came in at $548 million versus the consensus estimate of $510.14 million.
Third-Quarter 2020 Summary (comparisons to prior-year period)
Net sales of $548.0 million grew 20.1%; organic sales growth was 18.2%.Reported-diluted EPS of $1.09 increased 45%.Adjusted-diluted EPS of $1.15 increased 46%.Company is raising full-year 2020 net sales guidance to a new range of $2.10 billion and $2.11 billion.Company is raising full-year 2020 adjusted-diluted EPS guidance to a new range of $4.50 and $4.55."Adjusted-diluted EPS" and "organic sales... More
